Quantinno Capital Management LP Has $2.52 Million Stock Position in Caris Life Sciences, Inc. $CAI

Quantinno Capital Management LP raised its stake in Caris Life Sciences, Inc. (NASDAQ:CAI) by 117.0% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 140,909 shares of the company’s stock after buying an additional 75,987 shares during the quarter. Quantinno Capital Management LP’s holdings in Caris Life Sciences were worth $2,519,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. PointState Capital LP lifted its position in Caris Life Sciences by 73.0% in the 4th quarter. PointState Capital LP now owns 6,718,707 shares of the company’s stock valued at $181,271,000 after acquiring an additional 2,834,986 shares in the last quarter. UBS Group AG raised its stake in shares of Caris Life Sciences by 825.9% in the 4th quarter. UBS Group AG now owns 2,183,980 shares of the company’s stock valued at $58,924,000 after purchasing an additional 1,948,107 shares during the period. Balyasny Asset Management L.P. raised its stake in shares of Caris Life Sciences by 23,902.9% in the 4th quarter. Balyasny Asset Management L.P. now owns 1,660,280 shares of the company’s stock valued at $44,794,000 after purchasing an additional 1,653,363 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Caris Life Sciences by 185.0% in the fourth quarter. JPMorgan Chase & Co. now owns 2,445,281 shares of the company’s stock valued at $65,974,000 after purchasing an additional 1,587,176 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. grew its holdings in shares of Caris Life Sciences by 14.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 9,205,959 shares of the company’s stock worth $248,377,000 after buying an additional 1,180,200 shares in the last quarter.

Insider Activity at Caris Life Sciences

In other news, Director Jon Halbert bought 68,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The stock was acquired at an average cost of $14.56 per share, with a total value of $990,080.00. Following the completion of the purchase, the director owned 704,598 shares of the company’s stock, valued at $10,258,946.88. This represents a 10.68% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 50.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on CAI. Citigroup dropped their target price on Caris Life Sciences from $35.00 to $28.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. JPMorgan Chase & Co. decreased their price target on shares of Caris Life Sciences from $35.00 to $30.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Robert W. Baird set a $22.00 price objective on shares of Caris Life Sciences in a research report on Friday, May 8th. Jefferies Financial Group initiated coverage on shares of Caris Life Sciences in a report on Monday, April 13th. They set a “buy” rating and a $28.00 target price for the company. Finally, Weiss Ratings upgraded shares of Caris Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Seven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $26.33.

Caris Life Sciences Price Performance

CAI stock opened at $22.74 on Monday. The company has a quick ratio of 4.88, a current ratio of 5.53 and a debt-to-equity ratio of 0.66. The business has a 50 day moving average price of $17.22 and a two-hundred day moving average price of $18.70. The company has a market cap of $6.43 billion, a price-to-earnings ratio of 63.17 and a beta of 0.68. Caris Life Sciences, Inc. has a twelve month low of $14.19 and a twelve month high of $42.50.

Caris Life Sciences announced that its Board of Directors has approved a share repurchase plan on Monday, June 8th that permits the company to repurchase $100.00 million in shares. This repurchase authorization permits the company to buy up to 2.1% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its stock is undervalued.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.